Immunovant Stock Profit Margin
| IMVT Stock | USD 26.89 0.02 0.07% |
Immunovant fundamentals help investors to digest information that contributes to Immunovant's financial success or failures. It also enables traders to predict the movement of Immunovant Stock. The fundamental analysis module provides a way to measure Immunovant's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunovant stock.
| Last Reported | Projected for Next Year |
Immunovant | Profit Margin |
Immunovant Company Profit Margin Analysis
Immunovant's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Immunovant has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Immunovant Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovant's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics of similar companies.Immunovant is currently under evaluation in profit margin category among its peers.
Immunovant ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunovant's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunovant's managers, analysts, and investors.Environmental | Governance | Social |
Immunovant Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | 3.47 B | ||||
| Shares Outstanding | 146.78 M | ||||
| Shares Owned By Insiders | 55.64 % | ||||
| Shares Owned By Institutions | 54.57 % | ||||
| Number Of Shares Shorted | 13.1 M | ||||
| Price To Book | 8.78 X | ||||
| EBITDA | (269.98 M) | ||||
| Net Income | (259.34 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 138 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | (214.23 M) | ||||
| Short Ratio | 19.69 X | ||||
| Earnings Per Share | (2.21) X | ||||
| Target Price | 48.93 | ||||
| Number Of Employees | 207 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 3.94 B | ||||
| Total Asset | 666.37 M | ||||
| Retained Earnings | (825.68 M) | ||||
| Working Capital | 617.16 M | ||||
| Net Asset | 666.37 M |
About Immunovant Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.